PhRMA Uses Allergan Stage In Campaign To Keep Focus On Industry's Reputation For Innovation
PhRMA CEO Stephen Ubl visited Allergan's Irvine, Calif. R&D and manufacturing campus as the trade association continues its "Go Boldly" campaign promoting biopharma innovation in an effort to counteract the hit the industry's reputation has taken from drug pricing concerns.
You may also be interested in...
Amgen, Biogen, Pfizer and Teva generated more than twice their global R&D budgets with higher pricing in the US compared to Western Europe and Canada, researchers at Memorial Sloan Kettering found.
Allergan is building a diverse ophthalmology portfolio with a pipeline of drugs, devices and procedures that could bolster the company’s eye care revenue beyond Restasis and glaucoma medicines.
Drug industry executives discuss drug pricing and tax and regulatory reform in a high-profile meeting with President Trump at the White House.